Join to View Full Profile
6931 Arlington RdBethesda, MD 20814
Phone+1 301-907-2689
Dr. Campbell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Vanderbilt University Medical CenterFellowship, Pediatric Pulmonology, 1990 - 1993- Vanderbilt University Medical CenterResidency, Pediatrics, 1980 - 1983
University of Virginia School of MedicineClass of 1980
Certifications & Licensure
MD State Medical License 1998 - 2022
TN State Medical License 1982 - 1999
American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 39 citationsMicrobiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trialMarianne S. Muhlebach, Valeria V. Beckett, Elena B. Popowitch, Melissa B. Miller, Arthur Baines
Thorax. 2017-04-01 - 42 citationsForced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung FunctionWayne J. Morgan, Donald R. VanDevanter, David J. Pasta, Aimee J. Foreman, Jeffrey S. Wagener
The Journal of Pediatrics. 2016-02-01 - 113 citationsSweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial dataFrank J. Accurso, Fredrick Van Goor, Jiuhong Zha, Anne Stone, Qunming Dong
Journal of Cystic Fibrosis. 2014-03-01
Press Mentions
New Drug Appears to Slow Effects of Cystic Fibrosis, Offering Hope to Long-Suffering PatientsDecember 18th, 2019
Cystic Fibrosis Foundation Statement on FDA Approval of TRIKAFTA, the First Triple-Combination Therapy for the Most Common CF MutationNovember 7th, 2019
Preston W. Campbell, President and CEO of the Cystic Fibrosis Foundation to Retire; Michael P. Boyle, MD, Appointed as Successor Effective January 2020May 21st, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
